UFC light heavyweight Gian Villante has been cleared of a potential anti-doping violation by USADA.
The organization announced that Villante has been granted a retroactive therapeutic use exemption after disclosing the use of an inhaler during an out-of-competition drug test conducted on Jan. 18. The inhaler contained the substance vilanterol, which is listed as a Beta-2 Agonist (drugs that cause smooth muscle relaxation) and banned under World Anti-Doping Agency (WADA) code.
“Following his disclosure, USADA advised Villante that absent a valid TUE, the use of the inhaler was prohibited under the UFC Anti-Doping Policy. Thereafter, Villante submitted a TUE application documenting that his physician prescribed a 14-day course of the inhaler to treat conditions associated with airflow restriction and asthma,” the USADA statement read.
“Upon a thorough investigation into the circumstances surrounding Villante’s use of vilanterol, which included the retroactive TUE application process, USADA determined that the athlete had an unequivocally diagnosed acute medical condition for which the use of vilanterol is consistent with the standard of care. Further, it was determined that the short-term use of the Breo Ellipta inhaler was within the manufacturer’s therapeutic recommendation and was intended to return the athlete to a normal state of health without providing a performance-enhancing benefit. Finally, other permitted therapeutic alternatives were not successful at controlling the athlete’s condition.”
Since Villante was cleared of an anti-doping policy violation, he will remain on the March 11 UFC Fight Night 106 card against Mauricio Rua. Villante last appeared at UFC Fight Night 102, where he earned a second-round technical knockout victory over Saparbek Safarov on Dec. 9.